Top Markets
#1 ADO Protocol ADO Protocol +336.48%
#2 GoPlus Security GoPlus Security +50.52%
#3 Starpower Starpower +36.17%
#4 Fake World Assets Fake World Assets +29.96%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.56%
#6 GAIB AID GAIB AID +24.67%
#7 Nockchain Nockchain +22.31%
#8 The Black Bull The Black Bull +18.45%
#9 OpenEden OpenEden +14.53%
#10 Tutorial Tutorial +12.76%
Coin of the day
ADO Protocol ADO Protocol
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

CTXR
Rang în acțiuni #33050
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm... Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Preț acțiune
$0.5625
Capitalizare de piață
$6.29M
Schimbare (1 zi)
-25.56%
Schimbare (1 an)
-57.71%
Țară
US
Tranzacționează Citius Pharmaceuticals, Inc. (CTXR)

Categorie

Healthcare
Venituri pentru Citius Pharmaceuticals, Inc. (CTXR)
Venituri în Aug 2026 TTM: 0
Conform celor mai recente rapoarte financiare ale Citius Pharmaceuticals, Inc., venitul actual al companiei (TTM) este 0. În anul 2026, compania a avut un venit de 0 egal cu venitul din anul 2026, care a fost de 0. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Citius Pharmaceuticals, Inc. din 2026 până în 2026
Venituri la sfârșitul fiecărui an
An Venituri Schimbă
Nu sunt suficiente date pentru perioada selectată.
Venituri pentru companii similare sau concurente
Companie Venituri Diferență de venituri Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE